We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength in Technology Enabled Products Drives Roper: Can It Sustain?
Read MoreHide Full Article
Key Takeaways
ROP's Technology Enabled Products unit grew 6% organically on strong Neptune-driven demand.
Verathon and NDI strength support segment momentum headed into the fourth quarter.
ROP expects roughly 12.9% revenue growth in 2025, with organic sales rising about 6%.
Roper Technologies, Inc. (ROP - Free Report) is witnessing strong momentum in the Technology Enabled Products segment, driven by persistent strength in medical products businesses. Growth in demand for ultrasonic meters, cloud-based data and billing software solutions is fostering the growth of the Neptune business within the segment. In third-quarter 2025, the segment’s organic revenues increased 6% on a year-over-year basis.
Solid performance of the Verathon business, supported by strength across single-use BFlex & GlideScope offerings, bodes well for the segment. Also, healthy demand for cardiac, neurology and orthopedic precision measurement solutions is aiding the NDI business. Roper expects low-single-digit organic revenue growth for the segment in the fourth quarter of 2025.
Also, the growing popularity of its products and solutions across the Deltek, Vertafore, PowerPlan and Aderant businesses is driving ROP’s Application Software segment. This apart, strong momentum across alternate site healthcare, construction, and freight match markets, augurs well for its Network Software unit. Driven by strength across its businesses, the company expects total revenues to increase approximately 12.9% in 2025 from the year-ago level. Organic revenues are estimated to rise approximately 6% year over year.
Performance Snapshot of ROP’s Peers
Among its major peers, Agilent Technologies, Inc. (A - Free Report) has a significant exposure to the healthcare industry, which holds long-term prospects. Agilent’s strength in liquid chromatography systems and components and liquid chromatography mass spectrometry systems remains a plus. Also, strengthening demand for RF test equipment by medical device manufacturers remains a tailwind for Agilent.
Another peer, Honeywell International Inc. (HON - Free Report) , has been witnessing persistent weakness in the Industrial Automation segment. Softness in the productivity solutions and services business, owing to a decrease in license and settlement payments, remains a concern for Honeywell’s segment. In third-quarter 2025, Honeywell’s Industrial Automation segment’s sales declined 9% on a year-over-year basis.
ROP’s Price Performance, Valuation and Estimates
Shares of Roper have lost 11.8% in the past three months against the industry’s growth of 0.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 20.90X compared with the industry’s average of 25.31X. Roper carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ROP’s 2025 and 2026 earnings has declined over the past 60 days.
Image: Bigstock
Strength in Technology Enabled Products Drives Roper: Can It Sustain?
Key Takeaways
Roper Technologies, Inc. (ROP - Free Report) is witnessing strong momentum in the Technology Enabled Products segment, driven by persistent strength in medical products businesses. Growth in demand for ultrasonic meters, cloud-based data and billing software solutions is fostering the growth of the Neptune business within the segment. In third-quarter 2025, the segment’s organic revenues increased 6% on a year-over-year basis.
Solid performance of the Verathon business, supported by strength across single-use BFlex & GlideScope offerings, bodes well for the segment. Also, healthy demand for cardiac, neurology and orthopedic precision measurement solutions is aiding the NDI business. Roper expects low-single-digit organic revenue growth for the segment in the fourth quarter of 2025.
Also, the growing popularity of its products and solutions across the Deltek, Vertafore, PowerPlan and Aderant businesses is driving ROP’s Application Software segment. This apart, strong momentum across alternate site healthcare, construction, and freight match markets, augurs well for its Network Software unit. Driven by strength across its businesses, the company expects total revenues to increase approximately 12.9% in 2025 from the year-ago level. Organic revenues are estimated to rise approximately 6% year over year.
Performance Snapshot of ROP’s Peers
Among its major peers, Agilent Technologies, Inc. (A - Free Report) has a significant exposure to the healthcare industry, which holds long-term prospects. Agilent’s strength in liquid chromatography systems and components and liquid chromatography mass spectrometry systems remains a plus. Also, strengthening demand for RF test equipment by medical device manufacturers remains a tailwind for Agilent.
Another peer, Honeywell International Inc. (HON - Free Report) , has been witnessing persistent weakness in the Industrial Automation segment. Softness in the productivity solutions and services business, owing to a decrease in license and settlement payments, remains a concern for Honeywell’s segment. In third-quarter 2025, Honeywell’s Industrial Automation segment’s sales declined 9% on a year-over-year basis.
ROP’s Price Performance, Valuation and Estimates
Shares of Roper have lost 11.8% in the past three months against the industry’s growth of 0.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, ROP is trading at a forward price-to-earnings ratio of 20.90X compared with the industry’s average of 25.31X. Roper carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ROP’s 2025 and 2026 earnings has declined over the past 60 days.
Image Source: Zacks Investment Research
Roper currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.